Elena Ratner

Also affiliated with Yale University, Suffolk Horse Society

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.870Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors

Gynecologic Oncology(2023)10.1016/j.ygyno.2022.12.017

Top 23%

0.870DataRank

Top 23%21 citations

Tracy E. Crane, Austin Miller, Michael A. Gold, Matthew A. Powell, Kristin Bixel +15 more

Papers

Driven by 26 papers — median percentile 77. Top paper: “Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)”.

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)

Gynecologic Oncology(2020)10.1016/j.ygyno.2019.12.034

N/A

5.8DataRank · unranked

155 citations

Wei Deng, Michael Frumovitz, Natália Buza, Stefania Bellone, Warner K. Huh +7 more

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

Cancer(2021)10.1002/cncr.34025

N/A

2.4DataRank · unranked

80 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

Annals of Oncology(2021)10.1016/j.annonc.2021.04.013

N/A

1.9DataRank · unranked

50 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.01.028

N/A

0.879DataRank · unranked

31 citations

Cem Demirkiran, Tobias M.P. Hartwich, Stefania Bellone, Diego Manavella, Levent Mutlu +10 more

Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors

Gynecologic Oncology(2023)10.1016/j.ygyno.2022.12.017

Top 23%

0.870DataRank

Top 23%21 citations

Tracy E. Crane, Austin Miller, Michael A. Gold, Matthew A. Powell, Kristin Bixel +15 more

In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer

Scientific Reports(2021)10.1038/s41598-021-87325-5

N/A

0DataRank · unranked

11 citations

Nour N. Al Zouabi, Mark L. Xu, Nicole E. Bowen, Terence Wu, Ethan S. Lavi +5 more

Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.11.014

N/A

0DataRank · unranked

30 citations

Stefania Bellone, Diego Manavella, Levent Mutlu, Blair McNamara, Tobias M.P. Hartwich +17 more

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.05.005

N/A

0DataRank · unranked

25 citations

Paola Manara, Diego Manavella, Stefania Bellone, Tobias M.P. Hartwich, Justin Harold +17 more

Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib

Cancers(2023)10.3390/cancers15153919

N/A

0DataRank · unranked

8 citations

Mehida Rojas-Alexandre, Ruth E. Hanna, Z. Ping Lin, Elena Ratner, Cai M. Roberts

In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0126

N/A

0DataRank · unranked

8 citations

Diego Manavella, Stefania Bellone, Blair McNamara, Justin Harold, Dennis Mauricio +17 more

Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.03.009

N/A

0DataRank · unranked

4 citations

Justin Harold, Diego Manavella, Stefania Bellone, Levent Mutlu, Tobias M.P. Hartwich +24 more

Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild Type Ovarian Cancer Cells to Olaparib

Preprints.org(2023)10.20944/preprints202304.0327.v1

N/A

0DataRank · unranked

5 citations

Mehida Rojas-Alexandre, Ruth E. Hanna, Z Ping Lin, Elena Ratner, Cai M. Roberts

Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO)

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae177

N/A

0DataRank · unranked

28 citations

Justin C. Brown, MELINDA L. IRWIN, Kim Robien, Jessica M. Scott, Nathan A. Berger +88 more

Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2321898121

N/A

0DataRank · unranked

18 citations

Kyungjo Jeong, Mari K. Halle, Camilla Krakstad, Blair McNamara, Michelle Greenman +33 more

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2

Clinical & Experimental Metastasis(2024)10.1007/s10585-024-10297-z

N/A

0DataRank · unranked

9 citations

Blair McNamara, Stefania Bellone, Diego Manavella, Cem Demirkiran, Michelle Greenman +16 more

Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.04.010

N/A

0DataRank · unranked

9 citations

Michelle Greenman, Stefania Bellone, Blair McNamara, Tobias M.P. Hartwich, Diego Manavella +10 more

Preclinical Activity of Datopotamab Deruxtecan, an Antibody–Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma

Cancer Research Communications(2025)10.1158/2767-9764.crc-25-0057

N/A

0DataRank · unranked

6 citations

Cem Demirkiran, Stefania Bellone, Tobias M.P. Hartwich, Blair McNamara, Victoria M. Ettorre +7 more

CXCL10-induced regulatory T cells and adenosine signaling promote immunosuppression and progression of epithelial ovarian cancer

Scientific Reports(2025)10.1038/s41598-025-06812-1

N/A

0DataRank · unranked

4 citations

Jake Moscarelli, Yong-Lian Zhu, Z. Ping Lin, Elena Ratner, Annabelle C Lin

Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.06.017

N/A

0DataRank · unranked

3 citations

Stefania Bellone, Cem Demirkiran, Tobias M.P. Hartwich, Victoria M. Ettorre, Blair McNamara +7 more

Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor

International Journal of Molecular Sciences(2025)10.3390/ijms26188924

N/A

0DataRank · unranked

2 citations

Stefania Bellone, Victoria M. Ettorre, Miranda Mansolf, Tobias M.P. Hartwich, Blair McNamara +11 more

Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma

(2025)10.22541/au.174523361.14689067/v1

N/A

0DataRank · unranked

1 citations

Stefania Bellone, Cem Demirkiran, Tobias M.P. Hartwich, Victoria M. Ettorre, Blair McNamara +7 more

Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.03.094

N/A

0DataRank · unranked

0 citations

Danielle Enserro, Heather A. Lankes, Kyle C. Strickland, Rebecca A. Previs, Matthew Powell +19 more

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00118

N/A

0DataRank · unranked

64 citations

Salvatore Lopez, Burak Zeybek, Stefania Bellone, Elena Bonazzoli, Silvia Pelligra +17 more

Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.06.484

N/A

0DataRank · unranked

4 citations

Stefania Bellone, Luca Zammataro, Barbara Gnutti, Adele Guglielmi, Silvia Pelligra +15 more

Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)

Gynecologic Oncology Reports(2020)10.1016/j.gore.2019.100532

N/A

0DataRank · unranked

17 citations

Virginia L. Filiaci, Stefania Bellone, Roisin E. O’Cearbhaill, Elena Ratner, Cara Mathews +7 more

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

Gynecologic Oncology Reports(2020)10.1016/j.gore.2020.100554

N/A

0DataRank · unranked

8 citations

Natália Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner +4 more

Elena Ratner

Indexed papers

Top data-sharing exemplar

Papers